Increased risk of mental health problems after cancer during adolescence: a register based cohort study
Menée en Suède à partir de données portant sur 2 822 patients ayant survécu à un cancer pendant l’adolescence (âge au diagnostic : 13-19 ans) et sur 28 220 témoins, cette étude de cohorte analyse les facteurs associés au risque de troubles psychiques et à l’utilisation de médicaments psychotropes
Résumé en anglais
In this nationwide, register-based study, we estimated the risk of mental health problems in 2,822 individuals diagnosed with cancer in adolescence (13-19 years). Mental health problems were assessed by psychiatric diagnoses and/or prescribed psychotropic drugs. Cox proportional hazards models estimated hazard ratio (HR) for a psychiatric diagnosis and prescription of psychotropic drug compared to a matched comparison group (n=28,220). Estimates were adjusted for calendar period and parent characteristics (e.g., history of psychiatric diagnosis, education, country of birth). We found an increased risk of a psychiatric diagnosis during the first five years after the cancer diagnosis (females: HR 1.23, 95% CI, 1.06?1.44; males: HR 1.32, 95% CI, 1.11?1.56), and at >five years after diagnosis (females: HR 1.31, 95% CI, 1.09?1.58, males: HR 1.45, 95% CI, 1.18?1.77). The risk of being prescribed antidepressant? (females: HR 1.54, 95% CI, 1.30?1.84, males: HR 2.06, 95% CI, 1.66?2.55), antipsychotic? (females: HR 2.28, 95% CI, 1.56?3.34, males: HR 3.07, 95% CI, 2.13?4.42), anxiolytic? (females: HR 1.95, 95% CI, 1.64?2.31, males: HR 4.02, 95% CI, 3.34?4.84), and sedative drugs (females: HR 2.24, 95% CI, 1.84?2.72, males: HR 3.91, 95% CI, 3.23?4.73) were higher than for comparisons during the first five years after diagnosis. Median age at first psychiatric diagnosis and first prescribed psychotropic drug was 18?years. In conclusion, cancer during adolescence is associated with increased risk of mental health problems that may develop in close proximity to treatment. The findings emphasize the need for comprehensive care during treatment and follow?up.
